Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Completed × Neurofibroma × Clear all

Phase

Phase 2 6 Phase EARLY_PHASE1 2 Phase NA 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 236 Neoplasms 192 Carcinoma, Non-Small-Cell Lung 190 Leukemia, Myeloid, Acute 171 Multiple Myeloma 159 Colorectal Neoplasms 150 Prostatic Neoplasms 149 Melanoma 148 Leukemia 130 Lymphoma 129 Glioblastoma 119 Pancreatic Neoplasms 114 Lymphoma, Non-Hodgkin 113 Neoplasm Metastasis 105 Lung Neoplasms 104 Ovarian Neoplasms 103 Leukemia, Lymphocytic, Chronic, B-Cell 100 Precursor Cell Lymphoblastic Leukemia-Lymphoma 95 Myelodysplastic Syndromes 83 Hodgkin Disease 83 Recurrence 80 Lymphoma, Follicular 78 Lymphoma, Large B-Cell, Diffuse 77 Lymphoma, Mantle-Cell 74 Carcinoma, Renal Cell 72 Brain Neoplasms 72 Head and Neck Neoplasms 70 Carcinoma, Hepatocellular 66 Glioma 61 Colonic Neoplasms 61

Interventions

Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01140360 2017-07-02

0908-09

Indiana University

Phase 1/2 Completed

21 enrolled 8 charts

Neurofibroma, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon ⚡